Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

L.A. McKeown

February 18, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Daily News

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Shelley Wood

February 16, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Clears Next-Generation Sapien 3 Ultra TAVR Valve

Todd Neale

January 02, 2019

Advertisement

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Acoramidis Approved in Europe for ATTR Cardiomyopathy

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

FDA Grants MACE Reduction Indication for Semaglutide

Top Endovascular News of 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

TCTMD’s Top 10 Most Popular Stories for December 2021

British Medical Groups Express Concern About Inclisiran Rollout

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

FDA Approves Vericiguat for High-risk Patients With HF

Inclisiran Approved in Europe for Lowering LDL Cholesterol

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Clears Next-Generation Sapien 3 Ultra TAVR Valve

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content